HCPCS Level II code

J1441Description not available in NLM database

HCPCS Level IIVerified Sep 5, 2026

Medicare payment

No national Medicare fee schedule we hold prices J1441. CMS fee schedules ↗

Code definition

Code

J1441

Code system

HCPCS Level II

Full description

Description not available in NLM database

Policy activity for HCPCS J1441

CLV Intelligence is tracking 1 policy change that cite HCPCS J1441 most recently on 2026-07-23, drawn from 1 FDA notice. The changes span Oncology. 1 is flagged critical or high priority.

FDA notice
1

Counts reflect the source documents CLV has matched to HCPCS J1441 to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.

Recent policy changes matched to J1441

Matched to this code by CLV analysis of each policy. The linked source document is authoritative.

FDA Approval: NEUPOGEN (FILGRASTIM) — Type 1 - New Molecular Entity

Oncology

Government source· FDAverify ↗
See all alerts for J1441

Search J1441 across all alerts

Full history of CMS and MAC policy changes matched to this code.

Search all alerts →

Audit documentation

Building an audit file that includes HCPCS J1441?

The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

See audit packs — $349One-time purchase · not a subscription

Get alerts when policy changes affect J1441

Free weekly digest — no subscription required.

Get the free 90-day policy snapshot for your specialty

Free — no account required

See what CLV monitors for your specialty

Get a free 90-day sample snapshot — a PDF of every CMS and MAC policy change we tracked for your specialty and jurisdiction in the last quarter. Delivered instantly.

90-day windowPDF sample reportInstant download

By downloading, you agree to receive related policy update emails. You can unsubscribe at any time. Privacy policy